Biosignal: Collaboration with international company on agriculture applications
Evaluation for use in crop protection to be conducted over 9 months
Biosignal Limited has signed an agreement with a leading international agrichemicals company to evaluate its unique antimicrobial technology for use in crop and seed protection. The evaluation will be conducted at the facilities of, and fully funded by the partner company.
Biosignal's compounds are primarily in demand for their unique activity against bacterial biofilms, however in trials at Biosignal the compounds have also demonstrated a high level of activity against fungi. Fungal and bacterial pathogens cause significant damage to field crops, and result in the spoiling of seeds in storage and in the ground prior to germination. The agricultural sector is actively seeking novel and environmentally friendly treatments to combat these problems.
"Strategically, Biosignal is targeting the application of its technology in five key areas; industrial, agricultural, consumer, therapeutics and medical devices. These areas are ultimately anticipated to be separate business units or entities, and this deal is a positive early step in our strategy to establish a dedicated agricultural business," said Professor Peter Steinberg, CEO of Biosignal. 'We anticipate further developments in this field over the course of the year".
The evaluation will be conducted over the next 9 months with results expected early in 2009. The agreement is non-exclusive.
Organizations
Other news from the department business & finance

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.
Most read news
More news from our other portals
Last viewed contents
Morphochem and Probiodrug collaborate in research and development of novel innovative dipeptidyl peptidase IV - DP IV inhibitors for the treatment of Anxiety and Depression
Study Finds Ample Opportunities for Life Science Suppliers in the Biodefense Market

Clipster® Hand Held Tool for Size L | Sterile disconnectors | Sartorius
Merck Becomes the First to Use Acoustic Technology for Cell Therapy Manufacturing - Acquisition of FloDesign Sonics marks next step in autologous manufacturing
Dynavax Issued Landmark Patent Covering Second-Generation TLR9 Agonists
Lion_(company)
